Comparing the Effect of Transcranial Direct Current Stimulation (tDCS) With Cognitive-Behavioral therapy (CBT) Interventions on the stress and anxiety and depression and relapse in abstinent methamphetamine-dependent subjects in Farabi Hospital.

开始日期2022-07-23

申办/合作机构

Kermanshah University of Medical Sciences

NCT03825536 / Completed临床4期IIT

Short-term Effects of Methamphetamine Exposure on Residual Viral Transcription During Treated HIV Disease

The most commonly used illicit stimulant in HIV-infected individuals is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation. A challenge in achieving worldwide HIV eradication is targeting specific marginalized populations who are most likely to benefit from an HIV cure but possess poorer immune responses. For this study, HIV+ infected ART-suppressed individuals with no prior history of MA use disorder will be administered oral methamphetamine (the maximum FDA approved daily dose for the treatment of childhood obesity) to determine the effects of short-term MA exposure on residual virus production, gene expression, and inflammation. Measures of MA exposure in urine and serum will then be associated with residual virus production, gene expression, cell surface immune marker protein expression, and systemic markers of inflammation. The clinical trial data will generate advanced gene expression and immunologic data to identify potential novel targets for reversing HIV latency, reducing inflammation, and personalizing future therapies in HIV+ individuals who use MA.

开始日期2021-01-01

申办/合作机构

The University of California, San Francisco

[+1]

ACTRN12620000072910 / RecruitingN/AIIT

A pilot randomised controlled trial (RCT) testing the effect of personalised approach bias modification (vs. sham training) on abstinence from methamphetamine following discharge from rehabilitation in patients undergoing residential treatment for methamphetamine use disorder

开始日期2020-03-16

申办/合作机构

Monash University

100 项与盐酸去氧麻黄碱相关的临床结果

登录后查看更多信息

100 项与盐酸去氧麻黄碱相关的转化医学

登录后查看更多信息

100 项与盐酸去氧麻黄碱相关的专利（医药）

登录后查看更多信息

184

项与盐酸去氧麻黄碱相关的文献（医药）

2024-01-01·Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

Handheld UV spectrophotometer device for detection of methamphetamine hydrochloride based on supramolecular sensing platform

Article

作者: Yang, Long ; Zhang, Ruilin ; Yang, Hongxing ; Ran, Zhiyong ; Ran, Xin ; Yu, Yanbo ; Du, Guanben ; Tan, Xiaoping

The realization of drug detection in drug-using crime sites can provide law enforcement officials with direct evidence. This research has developed and demonstrated an easy-to-use handheld sensor that can quickly detect methamphetamine (MA) in the field. The core of the handheld UV spectrophotometer device (HUVSD) is the STM32F103 series of single-chip micro-controller, which has a 32-bit microcontroller and two embedded 12-bit high-precision analog-to-digital converter (ADC) modules. Through Bluetooth-wireless transmission protocol, the spectral information can be displayed in the cell phone's app, and it is possible to visually determine whether the test sample contains methamphetamine hydrochloride substances based on the characteristic peak at 410 nm. The readily available and inexpensive inducible compound 3A and the phosphate pillar[5]arene@silver nanoparticle (PP5@AgNPs) colloidal solution were used as the reactants. The PP5@AgNPs colloidal solution and 3A were mixed and reacted at room temperature, and the color changed to gray-black. The color change was caused by the aggregation of AgNPs induced by the molecular recognition between the induction compound 3A and PP5 on the AgNPs surface. After continuing to add the drug MA, the color of the colloidal solution turned yellow again. This is due to the occurrence of competitive molecular recognition, and the interaction between PP5 and 3A/MA was investigated by molecular docking simulations. The HUVSD has high sensitivity, simple equipment, time-saving, color change visualization and suitable for on-site deployment. It only needs a Pasteur pipette, which has great potential to realize rapid on-site detection.

2023-06-15·Research square

Brain Glutamate Dynamics Predict Positive Agency in Healthy Women.

作者: Harris, Ashley D ; White, Tara L ; Walsh, Edward G ; Gonsalves, Meghan A ; Joyce, Hannah E

Contributions of brain glutamate to conscious emotion are not well understood. Here we evaluate the relationship of experimentally-induced change in neocortical glutamate (ΔGlu) and subjective states in well individuals. Drug challenge with d-amphetamine (AMP; 20 mg oral), methamphetamine (MA; Desoxyn^®, 20 mg oral), and placebo (PBO) was conducted on three separate test days in a within-subjects double blind design. Proton magnetic resonance spectroscopy (MRS) quantified neurometabolites in the right dorsal anterior cingulate cortex (dACC) 140-150 m post-drug and PBO. Subjective states were assessed at half hour intervals over 5.5-hours on each session, yielding 3,792 responses per participant (91,008 responses overall, N=24 participants). Self-reports were reduced by principal components analysis to a single factor score of AMP- and MA-induced Positive Agency (ΔPA) in each participant. We found drug-induced ΔGlu related positively with ΔPA (ΔGluMA r=+.44, p<.05, N=21), with large effects in females (ΔGluMA r=+.52, p<.05; ΔGluAMP r=+.61, p<.05, N=11). States related to ΔGlu in females included rise in subjective stimulation, vigor, friendliness, elation, positive mood, positive affect (r's=+.51 to +.74, p<.05), and alleviation of anxiety (r=-.61, p<.05, N=11). Self-reports correlated with DGlu to the extent they loaded on ΔPA (r=.95 AMP, p=5×10^-10; r=.63 MA, p=.0015, N=11), indicating coherence of ΔGlu effects. Timing data indicated Glu shaped emotion both concurrently and prospectively, with no relationship to pre-MRS emotion (ΔGluAMP r=+.59 to +.65, p's<.05; ΔGluMA r=+.53, p<.05, N=11). Together these findings indicate substantive, mechanistic contributions of neocortical Glu to positive agentic states in healthy individuals, most readily observed in women.

2022-11-01·Journal of molecular neuroscience : MN

Prenatal Methamphetamine Hydrochloride Exposure Leads to Signal Transduction Alteration and Cell Death in the Prefrontal Cortex and Amygdala of Male and Female Rats’ Offspring

Article

作者: Khodagholi, Fariba ; Zare, Nayereh ; Maghsoudi, Nader ; Khakpour, Shahrzad ; Mansouri, Zahra ; Mirbehbahani, Seyed Hamidreza ; Ghorbani Yekta, Batool ; Foolad, Forough

In the last decade, there has been a great increase in methamphetamine hydrochloride (METH) abuse by pregnant women that exposes fetus and human offspring to a wide variety of developmental impairments that may be the underlying causes of future psychosocial issues. Herein, we investigated whether prenatal METH exposure with different doses (2 and 5 mg/kg) could influence neuronal cell death and antioxidant level in the different brain regions of adult male and female offspring. Adult male and female Wistar rats prenatally exposed to METH (2 or 5 mg/kg) and/or saline was used in this study. At week 12, adult rats' offspring were decapitated to collect different brain region tissues including amygdala (AMY) and prefrontal cortices (PFC). Western blot analysis was performed to evaluate the apoptosis- and autophagy-related markers, and enzymatic assay was used to measure the level of catalase and also reduced glutathione (GSH). Our results showed that METH exposure during pregnancy increased the level of apoptosis (BAX/Bcl-2 and Caspase-3) and autophagy (Beclin-1 and LC3II/LC3I) in the PFC and AMY areas of both male and female offspring's brain. Also, we found an elevation in the GSH content of all both mentioned brain areas and catalase activity of PFC in the offspring's brain. These changes were more significant in female offspring. Being prenatally exposed to METH increased cell death at least partly via apoptosis and autophagy in AMY and PFC of male and female offspring's brain, while the antioxidant system tried to protect cells in these regions.

项与盐酸去氧麻黄碱相关的新闻（医药）

2023-11-30

·GlobeNewswire-Health Care

Leading Specialist Material Handling Company, Titan Cranes and Rigging Pty Ltd., Adopts Intelligent Fingerprinting Drug Screening System

NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Titan Cranes and Rigging Pty Ltd. ("Titan") has adopted the Company's unique Intelligent Fingerprinting Drug Screening System. Since 2001, Titan has secured its spot as Australasia’s leading specialist material handling company, providing state-of-the-art lifting equipment and labor to the country’s largest construction projects. Australia’s construction industry is a key economic driver and employer for approximately 9.6% of workers1. The industry generates over $360 billion in annual revenue, producing about 9% of Australia’s gross domestic profit2. Titan has adopted INBS’ system across its operations as a new screening solution for its 350-plus employees. The Intelligent Fingerprinting Drug Screening System is a fast and accurate testing solution that utilizes fingerprint sweat to screen for specific drugs of abuse and provide results within minutes. A small tamper-proof cartridge collects the sweat samples, which are then analyzed by a reader to determine if an employee is fit for duty. The Company’s comprehensive solution also includes a lab-based confirmation service for non-negative on-site test results. Harry Simeonidis, President and Chief Executive Officer at Intelligent Bio Solutions, said, “Our drug screening product’s reputation is growing globally as a sound and reliable screening solution. We’re pleased to see our system being implemented by Titan as a non-invasive, clean, fast screening test, providing quick on-site results and supporting operational efficiency. We’re motivated to expand our reach further within the construction industry and assist more companies with mitigating drug use and potential impairment at work.” An introductory video demonstrating the Intelligent Fingerprinting Drug Screening System is available here. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: https://ibs.inc/ About Titan Cranes and Rigging Pty Ltd. Titan Cranes and Rigging Pty Ltd is a privately owned and operated Australian company. Established in 2001, the company has become a market leader for specialist material handling within the Australasian region. The core business for Titan Cranes and Rigging Pty Ltd is to provide specialist lifting equipment and personnel to construction projects. Its primary service is the delivery of tower cranes & hoists over a wide range of industries including government, residential, infrastructure, mining and commercial sectors. Titan is guided by its company vision, which is to always strive for business integrity, quality of service, a safe workplace, relationships management and commitment to each and every project. For more information, visit: https://titancranes.com.au/ Forward-Looking Statements: Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,"" estimates,"" anticipates,"" expects,"" plans,"" projects,"" intends,"" potential,"" may,"" could,"" might,"" will,"" should,"" approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact: Intelligent Bio Solutions Inc.New York Office: #646-790-5756info@ibs.incLinkedIn | Twitter Investor Relations:Valter Pinto, Managing DirectorKCSA Strategic Communications#(212) 896-1254INBS@kcsa.com Media Contact: Cheryl Billson Comma Communications cheryl.billson@commacomms.com 1 https://labourmarketinsights.gov.au/industries/industry-details?industryCode=E2 https://www.mordorintelligence.com/industry-reports/australia-construction-market

2023-11-29

·PRNewswire

Foundry Treatment Center Steamboat Now Proudly Accepts Medicaid From Rocky Mountain Health Plans

STEAMBOAT SPRINGS, Colo., Nov. 29, 2023 /PRNewswire/ -- Foundry Treatment Center Steamboat, part of NRT Behavioral Health™, now accepts Medicaid insurance plans from Rocky Mountain Health Plans. The ability to utilize Medicaid immediately makes desperately needed, high-quality, comprehensive treatment for addiction and co-occurring mental health disorders accessible to heavily impacted people with few local treatment resources. Starting today, individuals and families covered by Rocky Mountain Health Plans can use their Medicaid plans at the Foundry Treatment Center Steamboat men's residential program in Steamboat Springs, Colorado, and its intensive outpatient telehealth treatment for men and women. Foundry Treatment Center Steamboat is part of NRT Behavioral Health, a growing behavioral healthcare organization that operates Foundry Treatment Center Steamboat, Chrysalis Continuing Care in Denver, and the Michael Barnes Family Institute, offering telehealth to Colorado and Wyoming residents. NRT Behavioral Health works to expand the availability of its Trauma-Integrated Care, a highly trauma-centered approach to holistic treatment developed by Chief Clinical Officer Michael Barnes, Ph.D., using more than 40 years of research and clinical experience. The Trauma-Integrated Care model emphasizes reducing the risk of retraumatization, identifies and treats underlying trauma and PTSD to make healing and recovery possible, and helps families develop recovery-supportive lifestyles. Rural communities like those in Colorado's Western Slope and around the nation struggle with high rates of substance use and mental health disorders and lower access to treatment compared to urban and suburban areas. According to a report by the U.S. Department of Health and Human Services, rural communities experience 45 percent higher rates of opioid overdoses per capita than urban areas. Methamphetamine and misuse of multiple substances, such as alcohol in combination with other substances, also plague rural communities disproportionally. Suicide is another problem affecting these communities. A report from the Centers for Disease Control and Prevention indicates that the suicide rate in rural communities has risen twice as high as in metro areas in recent years. A lack of addiction and mental health treatment in rural areas compounds the problem. Foundry Treatment Center Steamboat outreach representatives Amanda Buckner and Amber King are rural Colorado natives who have been spearheading efforts to make treatment more accessible and reduce the stigma associated with addictive disorders. Buckner, King, and their colleagues began hosting virtual conferences for therapists and other mental health stakeholders in Colorado communities. These meetings, which aim to connect professionals and share resources and practices, have begun yielding results. Some attendees report that community members are starting support groups, and others see people speaking more openly about behavioral and mental health problems and seeking help. "When you grow up in rural communities like the ones we were raised in, substance misuse can be a very normal part of life. Whether people become dependent on pain medications after getting injured on physically demanding jobs or use alcohol and other substances to fit in or self-medicate anxiety, depression, and loneliness, substance use can go unnoticed or even be encouraged," says King. "We're starting to see some changes for the better," says Buckner. "The rural community I am from believes in 'pulling yourself up by your bootstraps.'" Finding empathy for fear, stress, or even grieving can be hard. Many still believe mental health and substance use disorders are personal weaknesses and that people are generally 'fine' unless they become unemployed or go to jail. But after years of losing so many loved ones to addiction and suicide, communities like mine are becoming more open to talking about trauma, and people in recovery are coming forward. We have a long way to go but see growing compassion, willingness to get treatment, and hope." The ability of Foundry Treatment Center Steamboat to accept Medicaid plans from Rocky Mountain Health can profoundly improve treatment availability. "Western Slope communities have some of the highest need and lowest recovery capital," says Foundry Treatment Center Steamboat Chief Operating Officer and NRT Behavioral Health Partner Tom Walker. "Our goal is to make accessing the high-quality, coordinated treatment services people need as easy as possible, and becoming a Rocky Mountain Health Plans provider represents a major leap forward. The negative effects of addiction, which can include trauma, alienation, and comorbid medical problems, can be amplified when they are allowed to persist, as is sometimes the case for people who live in rural communities. These individuals are experiencing the worst effects of the disease of addiction and need significant services. Our program is staffed by exceptionally experienced clinical leaders and provides high-quality treatment, trauma-informed therapies, family programming, psychiatric prescribing and medication management, aftercare planning, and alumni services that can help increase the odds of lasting recovery. Now that we are able to work with families using Rocky Mountain Health Plans, a very high quality of care is now far more accessible." In addition to Rocky Mountain Health Plans, Foundry Treatment Center Steamboat is also in-network with major insurance plans. If you or a loved one would like to learn more, please contact us at (844) 955-1066 or visit forgingnewlives.com. Media Contact: Tom Walker NRT Behavioral Health™ Chief Operating Officer tom.walker@foundrysteamboat.com SOURCE Foundry Treatment Center Steamboat

2023-11-29

·BioSpace

Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on December 7, 2023

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will present at the Emerging Growth Conference on December 7, 2023. The Company will provide insight into the Company’s unique proprietary Intelligent Fingerprinting Drug Screening System, among other topics. Harry Simeonidis, INBS’ President and Chief Executive Officer, is scheduled to present from 2:20 p.m. to 2:50 p.m. Eastern Time on Thursday, December 7, 2023. Link to register: Following the event, an archived webcast will be available on emerginggrowth.com and the Emerging Growth YouTube Channel: . A link to the webcast will be released after the event for convenient access. Attendees are encouraged to submit their questions in advance to Questions@EmergingGrowth.com or ask questions throughout the event. About the Emerging Growth Conference The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services, and other major announcements to the investment community from the convenience of their office, in a time efficient manner. The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. All sessions will be conducted through video webcasts and will take place in the Eastern time zone. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opioids, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including" believes,"" estimates,"" anticipates,"" expects,"" plans,"" projects,"" intends,"" potential,"" may,"" could,"" might,"" will,"" should,"" approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact: Intelligent Bio Solutions Inc. info@ibs.inc LinkedIn | Twitter Investor Contact: Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com Media Contact: Cheryl Billson Comma Communications cheryl.billson@commacomms.com +44 (0)7791 720460

100 项与盐酸去氧麻黄碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸去氧麻黄碱	N06BA03	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
注意缺陷障碍伴多动	美国	AJENAT PHARMACEUTICALS LLC	1943-12-31
抑郁症	日本	Sumitomo Pharmaceuticals Co., Ltd.	1941-01-01
发作性睡病	日本	Sumitomo Pharmaceuticals Co., Ltd.	1941-01-01
精神分裂症	日本	Sumitomo Pharmaceuticals Co., Ltd.	1941-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IAS2020	N/A	HIV感染	645	No methamphetamine use	鏇簾選鏇網範繭製襯艱(製壓遞顧糧繭淵觸範構): P-Value = 1.84	-	2020-01-01
				1-19 days of methamphetamine use
Hawaii Aging with HIV Cardiovascular Study (IAS2019)	N/A	HIV感染	43	never-used	鬱壓齋鹹顧築衊遞遞襯(壓選繭齋顧壓簾壓構積) = 繭觸鏇簾範築艱鏇觸選鏇觸憲鬱壓廠鹹糧衊齋 (鏇繭醖願鬱獵範蓋願鏇 )	-	2019-01-01
				recent-users	鬱壓齋鹹顧築衊遞遞襯(壓選繭齋顧壓簾壓構積) = 製鏇鬱獵獵願窪構窪鏇鏇觸憲鬱壓廠鹹糧衊齋 (鏇繭醖願鬱獵範蓋願鏇 )
NIDA P30DA011041 (IAS2017)	N/A	-	603	PWID using methamphetamine (Ice)	糧艱襯淵鏇鹹獵淵觸艱(廠壓鹹構鏇觸醖構獵壓) = 壓糧顧鹹選簾糧餘壓構願壓衊鬱壓夢顧觸繭觸 (選鏇選淵觸簾鬱獵築齋 ) 更多	-	2017-01-01
ISC2013	N/A	脑出血	384	Methamphetamine (Native Hawaiians and other Pacific Islanders)	窪餘壓衊夢廠壓廠膚範(壓醖鹹淵積壓鏇選顧糧) = 鏇壓膚壓選衊鑰齋遞壓觸壓範鬱襯鹽築衊齋範 (憲廠衊鹹獵獵構膚築顧 ) 更多	-	2013-02-01
				Methamphetamine (Non-Hispanic whites)	窪餘壓衊夢廠壓廠膚範(壓醖鹹淵積壓鏇選顧糧) = 選構夢壓餘簾觸範顧齋觸壓範鬱襯鹽築衊齋範 (憲廠衊鹹獵獵構膚築顧 ) 更多
IAS2012	N/A	药物滥用	-	Methamphetamine self-administration	壓夢鹽築壓積簾醖鹹窪(廠顧壓鹽觸淵鏇觸築獵) = 鬱蓋鬱醖膚構窪餘餘製選鬱網網鏇簾網衊壓製 (鹹構糧網顧範衊襯範淵 ) 更多	-	2012-01-01
IAS2007	N/A	HIV感染	-	Club drug users	醖蓋餘壓衊觸獵製憲憲(鹹鏇鹹製夢膚壓壓範鹽): OR = 2.28 (95% CI, 1.07 ~ 4.86) 更多	-	2007-01-01
				Non-club drug users
IAS2006	N/A	-	19,234	Methamphetamine-users	鬱憲選淵糧窪繭壓網夢(齋鑰範襯觸鬱蓋夢觸積): PR = 1.38 (99% CI, 1.23 ~ 1.55) 更多	-	2006-01-01
				Users of other stimulants